XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
N
N

Novartis

市场新闻

Reuters - 1天前

GSK sues Moderna for US patent infringement over COVID, RSV vaccines

UPDATE 2-GSK sues Moderna for US patent infringement over COVID, RSV vaccines Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna Adds information about RSV vaccine claims in paragraphs 1 and 6 By Blake Brittain Oct 15 (Reuters) - British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S.
G
N
P
Reuters - 6天前

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P
Reuters - 6天前

US judicial panel to examine litigation finance disclosure

US judicial panel to examine litigation finance disclosure By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers . After a decade of weighing whether it should do anything to regulate the emerging field of litigation finance, the U.S.
A
B
C
G
N
P
Reuters - 6天前

Swiss competition authority closes Novartis probe without consequences

UPDATE 1-Swiss competition authority closes Novartis probe without consequences Adds EU Commission in final two paragrahs BERLIN, Oct 10 (Reuters) - Switzerland's COMCO competition commission terminated an investigation against Novartis NOVN.S into possibly using blocking patents, without consequences, it said on Thursday. COMCO opened the probe in September 2022 to determine whether the pharmaceutical giant intended to unlawfully protect one if its medicines by filing various patent infringemen
N
Reuters - 1周前

Swiss competition authority closes Novartis probe without consequences

Swiss competition authority closes Novartis probe without consequences BERLIN, Oct 10 (Reuters) - Switzerland's COMCO competition commission terminated an investigation against Novartis NOVN.S into possibly using blocking patents, without consequences, it said on Thursday. COMCO opened the probe in September 2022 to determine whether the pharmaceutical giant intended to unlawfully protect one if its medicines by filing various patent infringement lawsuits, the commission said in a statement.
N
Reuters - 1周前

US lawmaker calls for litigation funding disclosures

US lawmaker calls for litigation funding disclosures By Sara Merken Oct 7 (Reuters) - A federal lawmaker has introduced legislation that would require the disclosure of third-party funding in civil lawsuits. U.S. Republican Representative Darrell Issa of California on Friday introduced a bill that calls for parties in civil litigation to tell the court and other named parties the identity of third-party that has the right to receive payment that is contingent on the outcome of a case or group or
A
B
C
G
N
P
Reuters - 1周前

Scholar Rock shares jump 300% after rare disease drug scores trial win

UPDATE 3-Scholar Rock shares jump 300% after rare disease drug scores trial win Adds analyst comments in paragraphs 6 and 7, similar drugs in paragraphs 5 and 8, updates shares By Christy Santhosh Oct 7 (Reuters) - Scholar Rock's SRRK.O experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading.
B
N
R
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P
Reuters - 2周前

US office real estate market shows signs of bottoming after big discount sales

ANALYSIS-US office real estate market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market Adds refinancing stats in paragraph 16, updates headline By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.
N
Reuters - 2周前

US office market shows signs of bottoming after big discount sales

ANALYSIS-US office market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.
N
Reuters - 2周前

Swiss stocks - Factors to watch on October 3

Swiss stocks - Factors to watch on October 3 ZURICH/GDANSK, Oct 3(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS Sika AG SIKA.S holds its Capital Markets Day. ANALYSTS' VIEWS NOVARTIS AG NOVN.S - JEFFERIES RAISES TARGET PRICE TO $124 FROM $123 ECONOMY Swiss September inflation data due at 0630 GMT.
N
S
S
Reuters - 3周前

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.
N
P
V
Reuters - 3周前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 3周前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 3周前

Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai

BRIEF-Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai Sept 24 (Reuters) - Novartis AG NOVN.S : GENERATE:BIOMEDICINES: ANNOUNCES MULTI-TARGET COLLABORATION WITH NOVARTIS TO DISCOVER & DEVELOP PROTEIN THERAPEUTICS WITH GENERATIVE AI GENERATE:BIOMEDICINES - POTENTIA
N
Reuters - 4周前

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
N
R
S
Reuters - 4周前

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S
Reuters - 4周前

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。